Clinical Trials | Research Study | MedStar Health

Find a clinical trial

Please use one or more of the field below to begin your search.

569 Results

Located at

With doctor

For patient age

All clinical trials

  • Protocol number: 00000370

    An Observational Study on the role of Hemophagocytosis in Patients with Anemia and Hemolytic Anemia

  • Protocol number: 015-00-E7080-G000-321

    A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) plus Lenvatinib (E7080/MK-7902) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic HER2 Negative Gastric/Gastroesophageal Junction Adenocarcinoma (LEAP-015)

  • Protocol number: 01AT21-MET

    A Phase 1/2 Open-Label, Dose-Escalation and Dose Expansion Study To Determine a Central Nervous System (CNS) Dose and Schedule Of Tepotinib Alone Or In Combination With Other Relevant Tyrosine Kinase Inhibitors (TKIS) In Adult Participants With MET-Driven NSCLC

  • Protocol number: 10445

    Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination With Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer

  • Protocol number: 14605760-MODEL-CRC

    MicroOrganoSphereTM (MOS) Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)

  • Protocol number: 1705018187-NCT04843566

    Randomized controlled trial assessing transperineal prostate biopsy to reduce infection complications

  • Protocol number: 19-047-NCT04139902

    Randomized Phase II Neoadjuvant Study of PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Resectable Stage III or Oligometastatic Stage IV Melanoma (Neo-MEL-T)

  • Protocol number: 20-041-NCP-NCT04264702

    BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

  • Protocol number: 2008-363

    Older Breast Cancer Patients: Risk for Cognitive Decline

  • Protocol number: 2013-0496

    A cross-over pilot study of the effect of amiloride compared to triamterene on proteinuria in patients with proteinuric kidney disease

  • Protocol number: 2014-0755

    Identifying children with diabetes type 1 at high risk for cardiovascular disease

  • Protocol number: 2014-1041

    Circulating Free DNA Molecular Tumor Response to Definitive Treatment

  • Protocol number: 2016-0220

    Molecular Epidemiology of Oxidative Stress and Related Cancers in Black Women

  • Protocol number: 2017-0440

    An Open Label, Phase I study to evaluate the impact of low doses of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Huntington’s Disease

  • Protocol number: 2017-0478

    STEPs to Blood Pressure Reduction. A Randomized Clinical Trial of the Stroke Transitions, Education, and Prevention Clinic Versus Usual Care for Post-Stroke Blood Pressure Reduction

  • Protocol number: 2017-0690

    MedStar Georgetown Transplant Institute Biorepository

  • Protocol number: 2017-0700-NCT03685461

    Intra- and Post-Operative Measures of Auditory Function

  • Protocol number: 2017-0838/GR412607

    Optimizing Bilateral and Single-Sided Deafness Cochlear Implants for Functioning in Complex Auditory Environments

  • Protocol number: 2017-0961

    MRI evaluation of recurrent disk herniation without post-contrast imaging using 3D T2 SPACE

  • Protocol number: 2017-1041-NCT03104517

    CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence

  • Protocol number: 2017-1316

    Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase I/II Multicenter, Randomized, Double Blinded, Safety Study (BRAVOS)

  • Protocol number: 2017-1393

    A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE

  • Protocol number: 2018-0191

    Investigation of the Effects of Radioactive Iodine on the Salivary Glands

  • Protocol number: 2018-0439

    A Randomized Trial of Proactive Outreach and Streamlined Genetic Education in BRCA Families

  • Protocol number: 2018-0979

    A Multi-center, Patient Outcome Registry for a Hydroxyapatite infused PEEK Interbody Fusion Device

  • Protocol number: 2018-1092

    A Retrospective Chart Review and analysis of oncologic patients undergoing curative or palliative treatments within the MedStar Georegetown University Hospital Interventional Radiology Department

  • Protocol number: 2018-173

    MedStar Plastic Reconstructive Surgery Outcomes Registry

  • Protocol number: 2018-242

    Outcomes Evaluation of the Medial Femoral Trochlea Flap for Reconstruction of the Scaphoid and Lunate

  • Protocol number: 2019-1

    A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients

  • Protocol number: 208090

    A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed

  • Protocol number: 209035

    A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 infected Adults who are Virologically Suppressed and Participated in Study LAI116482

  • Protocol number: 221AD304

    A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (EMBARK)

  • Protocol number: 54767414MMY3021

    A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

  • Protocol number: 718-CIH-201

    A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington s Disease

  • Protocol number: 718-CIH-202

    A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants with Huntington's Disease

  • Protocol number: A011801-COMPASSHER-NCT04457596

    The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

  • Protocol number: A021502

    RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR

  • Protocol number: A021703-SOLARIS-NCT04094688

    Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

  • Protocol number: A021806-NCT04340141

    A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

  • Protocol number: A031702-NCT03866382

    A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

  • Protocol number: A031704-PDIGREE-NCT0379316

    A031704, PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab in metastatic untreated REnal Cell CancEr [PDIGREE]

  • Protocol number: A031803-NCT04164082

    Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

  • Protocol number: A031902-CASPAR

    CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

  • Protocol number: A041703-NCT03739814

    A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

  • Protocol number: A081801-NCT04267848

    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study

  • Protocol number: A082002

    A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

  • Protocol number: A151216-ALCHEMIST-NCT02194738

    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

  • Protocol number: A221805

    DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY

  • Protocol number: A231601CD-OPTI-SURGNCT03857620

    Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

  • Protocol number: AALL1731-NCT03914625

    A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

  • Protocol number: AALL1732-NCT03959085

    A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

  • Protocol number: AAML1831-NCT04293562

    A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.

  • Protocol number: AAML18P1-NCT03817398

    Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  • Protocol number: ABBVIEM20-339

    Parkinson's Disease: A Comparative Study of Levodopa and Carbidopa Bioavailability Following Foslevodopa/foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease Patients

  • Protocol number: ABOLISH

    INTERNATIONAL, MULTICENTRE, OBSERVATIONAL, PROSPECTIVE, LONGITUDINAL STUDY TO ASSESS THE EFFECTIVENESS OF ABOBONT-A INJECTIONS FOR ADULT LOWER LIMB SPASTICITY IN A REAL LIFE COHORT (ABOLISH)

  • Protocol number: ACCRU-GI-1611-NCT03765736

    COLOMATE: COlorectal Cancer Liquid BiOpsy Screening Protocol for Molecularly Assigned ThErapy

  • Protocol number: ACCRU-GI-1809-NCT04117945

    A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR monoclonal antibody therapy Versus the Reverse Sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan (REVERCE II)

  • Protocol number: ACNS1422-NCT02724579

    A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

  • Protocol number: ACT17209

    A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia

  • Protocol number: ACURATE-NCT03735667

    Transcatheter Replacement of Stenotic Aortic Valve through Implantation of ACURATE in Subjects InDicatEd for TAVR

  • Protocol number: ADAMAS301-NCT03436199

    A 3-ARM, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT

  • Protocol number: ADAP-008-NCT04545333

    Real World Observational Study using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The Watch Registry

  • Protocol number: ADMIRE-BWI201910

    Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI IRE Ablation System

  • Protocol number: ADNI3-NCT02854033

    Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)

  • Protocol number: ADVL1823-NCT03834961

    Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemia

  • Protocol number: AFFINITY-NCT03222973

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

  • Protocol number: AFT-50-NCT04486352

    A Phase IB/II Multi-Cohort Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

  • Protocol number: AGAREGISTRY

    Fecal Microbiota Transplant National Registry

  • Protocol number: AGCT1531-NCT03067181

    A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

  • Protocol number: AGCT1532-NCT02582697

    Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

  • Protocol number: AGT-HC168

    Phase I Study to Evaluate the Safety of Genetically Modified, Autologous T Cells in Participants with HIV that is Well-Controlled on Antiretroviral Therapy

  • Protocol number: AGT-HC169

    American Gene Technologies AGT-HC169

  • Protocol number: AGT103-T-LTFU

    A Long-Term Follow-Up Study of Participants Treated with the LentiviralBased Genetically Modified, Autologous Cell Product, AGT103-T

  • Protocol number: AHEAD3-45

    AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer s Disease and Intermediate Amyloid (A3 Trial)

  • Protocol number: AHEP1531-NCT03533582

    Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

  • Protocol number: AIBERRY-STUDY00003473

    Developing an A.I. Platform to Detect Depression Predict depression at higher degree of accuracy Implement the Aiberry platform in a live environment

  • Protocol number: AIMPOWER-NCT04191330

    Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors

  • Protocol number: AIMSS

    Improving Adherence to Aromatase Inhibitor therapy in early-stage breast cancer by early physiatry consultation to decrease AIMSS

  • Protocol number: ALCOHOLICHEPATITIS

    Outcomes of Alcoholic Hepatitis and Alcohol Cirrhosis Patients after Liver Transplant

  • Protocol number: ALIGN-AR-NCT04415047

    A Study to Assess Safety and Probable Benefit of the Transfemoral JenaValve Pericardial TAVR System in the Treatment of High Surgical Risk Patients with Symptomatic, Severe Aortic Regurgitation (AR)

  • Protocol number: ALLIANCE-NCT05172960

    Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve

  • Protocol number: ALLO-316-101-NCT04696731

    A PHASE 1 MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF ALLO-316 FOLLOWING ALLO-647 CONTAINING CONDITIONING REGIMEN IN SUBJECTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA (ccRCC)

  • Protocol number: ALTAVALVE-NCT03997305

    AltaValve Early Feasibility Study Protocol

  • Protocol number: ALTE1631-NCT03223753

    A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer

  • Protocol number: ALTE2031-NCT04089358

    StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors

  • Protocol number: AMG423-SHAH-NCT02929329

    Registrational Study to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

  • Protocol number: AML-PROSPECTIVE-STUDY00000298

    A Pilot Study to Evaluate Physical Function and Fatigue in Patients with Acute Myeloid Leukemia Single Center Prospective Cohort Study

  • Protocol number: AML-RETROSPECTIVE- STUDY00001361

    A center-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia (AML)

  • Protocol number: AMPLATZER-PFO-NCT03309332

    AMPLATZER PFO Occluder Post Approval Study (PFO PAS)

  • Protocol number: ANBL1232-NCT02176967

    Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

  • Protocol number: ANHL1931-NCT04759586

    Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Protocol number: ANX-WAIHA-01

    A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia

  • Protocol number: ANX005-HD-001

    A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects with, or at Risk for, Manifest Huntington’s Disease

  • Protocol number: ANX005-WAIHA-02

    A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of- Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolytic Anemia

  • Protocol number: APEC14B1

    APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

  • Protocol number: APEC1621SC-NCT03155620

    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

  • Protocol number: APOL-1

    Integrating a Culturally Competent APOL1 Genetic Testing Program into Living Donor Evaluation

  • Protocol number: APOLLO-NCT03242642

    Transcatheter Mitral Valve Replacement with the Medtronic Intrepid TMVR System in patients with severe symptomatic mitral regurgitation APOLLO Trial

  • Protocol number: APOLLO-NCT03615235

    APOL1 LONG-TERM KIDNEY TRANSPLANTATION OUTCOMES NETWORK (APOLLO)

  • Protocol number: ARCADIA-NCT03192215-NRH

    AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)

  • Protocol number: AREN03B2

    Renal Tumors Classification, Biology and Banking Study

  • Protocol number: AREN1921-NCT04322318

    Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors(DAWT)and Relapsed Favorable Histology Wilms Tumors(FHWT)

  • Protocol number: ARGX-113-2004

    A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

  • Protocol number: ARGX-113-2005

    A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

  • Protocol number: ARIES-HM3-NCT04069156

    Antiplatelet Removal and HemocompatIbility EventS with the HeartMate 3 Pump

  • Protocol number: ARST1431-NCT02567435

    A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

  • Protocol number: ARST1921-NCT04195399

    ARST1921 A Safety, Pharmacokinetic and Efficacy Study of a γ-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors

  • Protocol number: ARTESIA-NCT01938248

    Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial fibrillation

  • Protocol number: ASAPTOO-SHA-NCT02928497

    Assessment of the WATCHMANTM Device in Patients Unsuitable for Oral Anticoagulation ASAP-TOO

  • Protocol number: ATA129-EBV-302-NCT03394365

    Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

  • Protocol number: ATN-106

    A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing surgery or delivery

  • Protocol number: ATRC-101-A01

    A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies

  • Protocol number: ATRI-004

    In-Clinic Trial-Ready Cohort (TRC-PAD)

  • Protocol number: AURORAUS-NCT03737695

    AURORA US: PROSPECTIVE BIOSPECIMEN REPOSITORY IN METASTATIC BREAST CANCER

  • Protocol number: AVEIR

    Aveir Dual-Chamber Leadless i2i IDE Study

  • Protocol number: B-60-NCT04622319

    A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY (T-DXd vs. T-DM1 in high-risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy)

  • Protocol number: BAN2401-G000-301

    A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer s Disease.

  • Protocol number: BBI-20201001-NCT04278144

    Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2- Expressing Solid Tumors

  • Protocol number: BEAR

    Bridge-Enhanced ACL Repair (BEAR)

  • Protocol number: BESTREGISTRY-NCT04191746

    BEST-Registry

  • Protocol number: BHV3500-203

    BHV3500-203: Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients with COVID-19 Requiring Supplemental Oxygen

  • Protocol number: BIODESIX

    A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Classifier in Incidentally Discovered Low to Moderate Risk Lung Nodules

  • Protocol number: BIOREC

    Biomarkers of Stroke Recovery Study

  • Protocol number: BIOTIN

    Effect of Biotin in thyroid laboratory exams

  • Protocol number: BMTCTN1903-NCT04975698

    Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST

  • Protocol number: BOND-003

    A Phase 3 Study of CG0070 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

  • Protocol number: BOSUTINIB-WI231696

    A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor (ASPIRE - WI231696)

  • Protocol number: BP-LVAD

    Blood Pressure and Outcomes in Contemporary Left Ventricular Assist Device Recipients

  • Protocol number: BQ5-NCT05044507

    The efficacy of a frequency-tuned electromagnetic field treatment in facilitating the recovery of subacute ischemic stroke patients a pivotal study

  • Protocol number: BURN-RADIATION

    A Systems Biology Approach to Radiation Biodosimetry and the Host- Environment Interaction: Applications to Mass Casualty Triage in the Polytrauma Patient.

  • Protocol number: C-14

    CORRECT-MRD II: SECOND COLORECTAL CANCER CLINICAL VALIDATION STUDY TO PREDICT RECURRENCE USING A CIRCULATING TUMOR DNA ASSAY TO DETECT MINIMAL RESIDUAL DISEASE

  • Protocol number: C3441052-NCT04821622

    TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

  • Protocol number: C4221015-NCT04607421

    AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER

  • Protocol number: C4671034

    A Study to Learn About the Study Medicines Called Nirmatrelvir/Ritonavir in People at Least 12 Years of Age With COVID-19 Who Are Immunocompromised

  • Protocol number: CA2098TT-NCT03899155

    Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab

  • Protocol number: CA224-098-NCT05002569

    A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma

  • Protocol number: CA42481

    A Phase II, Open-Label, Randomized, Multicenter Study To Investigate the Pharmacodynamics, Pharmacokinetics, Safety and efficacy of 8mg/kg or 4mg/kg Intravenous Tocilizumab in Patients with moderate to severe COVID-19 Pneumonia

  • Protocol number: CAAA617C12301

    An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  • Protocol number: CAD

    Hand arterial calcification as a predictor for subclinical coronary artery disease using coronary artery calcium scoring.

  • Protocol number: CAD-DECISIONAID

    Shared Decision Making in the Prevention and Management of Cardiovascular Disease

  • Protocol number: CAPTIVA-NCT05047172

    CAPTIVA is a two-stage Phase III trial randomizing subjects with stroke attributed to 70-99% intracranial atherosclerotic stenosis (sICAS) to: 1) ticagrelor + aspirin 2) low dose rivaroxaban + aspirin 3) clopidogrel + aspirin The primary goal of the trial is to determine if the experimental arm(s) (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of the primary endpoint (ischemic stroke, intracerebral hemorrhage (ICH), or vascular death). The first stage of the trial is concluded by an interim safety analysis intended to identify an excess of parenchymal intracerebral hemorrhage (ICH) or non-ICH major hemorrhage with ticagrelor + aspirin or low dose rivaroxaban + aspirin that could lead to an early termination of one or both of those arms. The second stage of the trial will determine if the experimental arm(s) (rivaroxaban or ticagrelor or both) that progress to stage 2 are superior to the clopidogrel arm for lowering the 1-year rate of the primary endpoint (ischemic stroke, intracerebral hemorrhage (ICH), or vascular death). An exploratory aim is to estimate the impact of CYP2C19 loss-of-function (LOF) carrier status on any benefit that the ticagrelor or low dose rivaroxaban arms may have in lowering the primary endpoint compared with the clopidogrel arm.

  • Protocol number: CARDIAMP-NCT02438306

    Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy in Patients With Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)

  • Protocol number: CARDUS-HANDHELD

    Handheld Cardiac Ultrasound in Resident Assessment of Left Ventricular Ejection Fraction in Outpatients

  • Protocol number: CARES

    Multi-level interventions to manage co-morbidities among Black breast and prostate cancer patients

  • Protocol number: CARILLON-NCT03142152

    Assessment of the Carillon® Mitral Contour System® in Treating Functional Mitral Regurgitation Associated With Heart Failure - The CARILLON Trial

  • Protocol number: CATALYST-NCT04226547

    Clinical trial of atrial fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants

  • Protocol number: CCTGMA39-NCT03488693

    TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

  • Protocol number: CERCLAGEEFS-NCT03929913

    NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty early feasibility study

  • Protocol number: CGT9486-21-301-PEAK

    A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors (PEAK)

  • Protocol number: CGX1321-101-NCT02675946

    A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects With Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Gastrointestinal Tumors

  • Protocol number: CHAMPION-AF

    WATCHMAN FLX versus NOAC for EMbolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation

  • Protocol number: CHIMES-NCT04377555

    AN OPEN-LABEL, MULTICENTER STUDY TO ASSESS DISEASE ACTIVITY AND BIOMARKERS OF NEURONAL DAMAGE IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH OCRELIZUMAB

  • Protocol number: CITR

    Collaborative Islet Transplant Registry

  • Protocol number: CLASP-IID-NCT03706833

    Edwards PASCAL TrAnScatheter Mitral Valve RePair System Pivotal Clinical Trial (CLASP IID): A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Mitral Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR).

  • Protocol number: CLR1806-NCT03655236

    A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF K0706 IN SUBJECTS WITH EARLY PARKINSON S DISEASE

  • Protocol number: CMRI-DIASTOLIC

    Diastolic Dysfunction on Cardiac MRI

  • Protocol number: CNMC-

    Bio-repository for Cells, Tissue, Blood, Urine and DNA

  • Protocol number: COE-002-1116

    Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Retrospective Outcomes-Associated Database

  • Protocol number: COLOPLAST-INTIBIA

    A Prospective, Randomized Clinical Trial Evaluating INTIBIA, an Investigational Implantable Tibial Nerve Stimulator, Through 24-Months.

  • Protocol number: COMBINE1-4591

    A 52-week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti-diabetic drugs, in participants withtype 2 diabetes inadequately controlled with daily basal insulin. COMBINE 1

  • Protocol number: COMBINE2-4592

    A 52-week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist. COMBINE 2

  • Protocol number: COMBINE3-4593

    A 52-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL combined with insulin aspart, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin. COMBINE 3

  • Protocol number: COMET-NCT02926911

    COMET-Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

  • Protocol number: COMPARTMENTSYNDROME

    Non-Invasive Observational Study of Extremity Compartment Syndrome Using Philips Ultrasound Shear Wave Elastography and Micro-vascular Flow Imaging

  • Protocol number: CONFIDES-NCT04935177

    A Phase III Randomized Controlled Trial to Evaluate 1-Year eGFR in Highly Sensitized (cPRA Greater than or equal to 99.9%) Deceased Donor Kidney Transplant Recipients, Following Imlifidase-Inactivation of HLA Antibodies Prior to Transplantation

  • Protocol number: CONNECT-HF-NCT03035474

    CARE OPTIMIZATION THROUGH PATIENT AND HOSPITAL ENGAGEMENT CLINICAL TRIAL FOR HEART FAILURE CONNECT-HF

  • Protocol number: CONVERGEPAS

    Post-Approval Study Protocol For Hybrid Convergent Of Epicardial RF Ablation And Endocardial Ablation For The Treatment Of Symptomatic Long-standing Persistent AF

  • Protocol number: CORCINCH-HF

    Randomized Clinical Evaluation of the AccuCinch® Ventricular Repair System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)

  • Protocol number: CORCINCH-NCT03533517

    Randomized Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)

  • Protocol number: COREVNS-NCT03529045

    Comprehensive Outcomes Registry in Subjects with Epilspsy Treated with Vagus Nerve Stimulation Therapy

  • Protocol number: CORMATRIX-NCT02397668

    CORMATRIX® COR™ TRICUSPID ECM® VALVE REPLACEMENT SAFETY AND EARLY FEASIBILITY STUDY

  • Protocol number: COVID-ARC-19-NCT04401449

    Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19)

  • Protocol number: COVID-CALYPSO

    COVID-19 associated Lymphopenia Pathogenesis Study in Blood

  • Protocol number: COVID-REP0321

    Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19. A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial.

  • Protocol number: CYNK-101-HER2-001-NCT05207722

    A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aenocarcinoma

  • Protocol number: CYTOKINETICS-CY6031

    A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CK-3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION

  • Protocol number: D7310C00001-NCT04590963

    A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

  • Protocol number: D8850C00006

    Open-label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged &#8805; 29 Weeks Gestational Age to < 18 Years

  • Protocol number: D9103C00001-PACIFIC4-WHC

    A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • Protocol number: D910PC00001-VOLGA

    A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

  • Protocol number: D926PC00001-TROPION-02

    A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) VersusInvestigator s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02)

  • Protocol number: DCCOHORT

    HRSA DC COHORT

  • Protocol number: DCCOHORT-COVID

    Measuring the Impact of COVID-19 among and Urban Cohort of PLWH in Washington DC.

  • Protocol number: DCL-16-001-NCT02952508

    An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-I) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)

  • Protocol number: DCM-CMR-STUDY

    Dilated Cardiomyopathy (DCM) Research Project Sub-study: Advanced Procedures Sub-Study

  • Protocol number: DCP-002

    Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate among Racially and Ethnically Diverse Populations

  • Protocol number: DEBIO1143-SCCHN-NCT04459715

    A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity- modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).

  • Protocol number: DEFINE-GPS

    Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting

  • Protocol number: DERMACELL

    A Randomized, Prospective Trial Comparing the Clinical Outcomes for DermACELL® Compared with Integra® Bilayer Wound Matrix

  • Protocol number: DEXTERITY-CIP0217

    DEXTERITY-AFP: Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation after Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT

  • Protocol number: DEXTERITY-CIP0218

    DEXTERITY-SCI: Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation after Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

  • Protocol number: DFU-GSH

    Randomized Clinical Trial to Compare Transforming Powder and Standard of Care Dressing Therapies to Heal Diabetic Foot Ulcers

  • Protocol number: DFU-WHC

    Randomized Clinical Trial to Compare Transforming Powder and Standard of Care Dressing Therapies to Heal Diabetic Foot Ulcers

  • Protocol number: DIRECTION-NCT04936542

    A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity

  • Protocol number: DIS-DMTMS

    Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

  • Protocol number: DISCOMS-NCT03073600

    Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

  • Protocol number: DISRUPTPAD-BTKII

    Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries

  • Protocol number: DLS-HCV-MUMH-NCTNA

    The collection of biological specimens with comparison data from subjects that will be catalogued in a biorepository for research

  • Protocol number: DLS-NCTNA

    Collection of Bio-fluid Samples from Pregnant Women for the Evaluation of Biomarkers for Preeclampsia

  • Protocol number: DOD-ADNI-NCT01687153

    Effects of traumatic brain injury and post traumatic stress disorder   on Alzheimer’s disease (AD) in Veterans using ADNI (DOD ADNI)

  • Protocol number: DRESSINGCOMPARRISON

    A Comparison of Split-thickness Skin Graft Primary Dressings When Used with Autologous Skin Cell Suspension.

  • Protocol number: DURECTAH

    A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis

  • Protocol number: EA1151-TMIST-NCT03233191

    Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA 1151

  • Protocol number: EA2174-NCT03604991

    A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

  • Protocol number: EA2182-NCT04166318

    A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

  • Protocol number: EA2185-PANCREATIC-NCT04239573

    Comparing Two Methods to Follow Patients With Pancreatic Cysts

  • Protocol number: EA2186-GIANT

    A Randomized Phase II Study of Gemcitabine and Nab Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

  • Protocol number: EA3191

    A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

  • Protocol number: EA3202

    A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

  • Protocol number: EA6141-NCT02339571

    Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

  • Protocol number: EA6174-NCT03712605

    STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

  • Protocol number: EA6191

    The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAFV600E/K Melanoma with elevated LDH

  • Protocol number: EA6192

    A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

  • Protocol number: EA8184

    A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

  • Protocol number: EA8192

    A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

  • Protocol number: EARLYTAVR-NCT03042104

    Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis: EARLY TAVR trial

  • Protocol number: EASESBS1-NCT03690206

    A PHASE 3, INTERNATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF GLEPAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME (SBS)

  • Protocol number: EASESBS2EXT-NCT03905707

    A Double-Blind Phase 3 Extension Trial Assessing the Long-Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel

  • Protocol number: ECGBELT-NCT03504020

    ECG Belt for CRT Response

  • Protocol number: EEG-ENDO

    Investigation of pre-operative electroencephalogram (EEG) based central sensitivity measurements on surgical outcomes for patients undergoing operative laparoscopy for endometriosis diagnosis and treatment.

  • Protocol number: EIDOS-AG10-304

    EIDOS-AG10-304

  • Protocol number: EKO

    Real-World Evaluation of Eko Murmur Analysis Software in a Point of Care Setting

  • Protocol number: EKO-LOWEF-NCT04400435

    Detection of Reduced Left Ventricular Ejection Fraction and Atrial Arrhythmias with Single Lead ECG using Artificial Intelligence

  • Protocol number: ELEGANCE-REGISTRY

    ELEGANCE Drug-ELuting REGistry: ReAl-World Treatment of LesioNs in the Peripheral VasCulaturE

  • Protocol number: ELVCAP-001-01-NCT04383210

    A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

  • Protocol number: EMPACT-MI

    EMPACT-MI: A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction

  • Protocol number: EMPAKIDNEY-NCT03594110

    A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease

  • Protocol number: EMPOWER-NCT04598698

    EMPOWER: Endometriosis diagnosis using MicroRNA: PrOspective study in Women to allow Early disease Recognition

  • Protocol number: ENCIRCLE-NCT04153292

    The ENCIRCLE Trial SAPIEN M3 System TransCatheter MItral Valve ReplaCement via TransseptaL AccEss

  • Protocol number: ENLIGHTEN-NCT04140305

    A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

  • Protocol number: EPROMPT-CA

    CoreValve Evolut PRO Prospective Registry

  • Protocol number: EPROMPT-NCT03423459

    CoreValve Evolut PRO prospective registry

  • Protocol number: ES201601-NCTNA

    Blood Sample Collection in Subjects with Pulmonary Nodules or CT Suspicion of Lung Cancer

  • Protocol number: ESR-18-13870

    A Phase II Trial of Durvalumab (MEDI4736) in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

  • Protocol number: ETCTN10166-NCT03600701

    A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

  • Protocol number: ETCTN10334

    BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy

  • Protocol number: EV-ICD

    ExtraVascular Implantable Cardioverter Defibrillator (EV ICD) Pivotal Study

  • Protocol number: EVA-26242-01

    Understanding the Patient-reported Symptoms and impacts of Diffuse and Limited Cutaneous Systemic Sclerosis

  • Protocol number: EVAULT

    Long-term outcomes following vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study (eVAULT)

  • Protocol number: EXT00000206-PRELUDE

    A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy

  • Protocol number: FAMI

    Functional Arm Use After Musculoskeletal Injury as a Measure of Recovery

  • Protocol number: FARAPULSE-ADVENT-NCT04612244

    A Prospective Randomized Pivotal Trial of the FARAPULSE Pulsed Field Ablation System Compared with Standard of Care Ablation in Patients with Paroxysmal Atrial Fibrillation

  • Protocol number: FAST

    Functional Arm Use After Stroke (FAST) as a Measure of Motor Recovery After Stroke

  • Protocol number: FAST-ULTRASOUND

    Abdominal FAST imaging of Adult Trauma Patients to Build an Annotated Ultrasound Image Library for Development of Automated Ultrasound Image Acquisition and Interpretation Algorithms.

  • Protocol number: FENTREPID

    A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  • Protocol number: FEVAR-NCT04526938

    Clinical Outcomes, Radiation Dosage, and Quality of Life in Patients Treated with Fenestrated Stent Grafts for Complex Thoracoabdominal and Abdominal Aortic Aneurysms, and Thoracoabdominal Aortic Aneurysms secondary to Aortic Dissections

  • Protocol number: FFP

    Identification of Mechanisms Underlying the Effects of Plasma Inclusive Resuscitation in Major Thermal Injury on Hemostasis and Vascular Homeostasis

  • Protocol number: FGCL-3019-091

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

  • Protocol number: FREEDOM--NCT03995901

    A 5-year, randomized, controlled, multi-center study to assess the safety and efficacy of FCR001 cell-based therapy relative to tacrolimus and mycophenolate mofetil in de novo living donor renal transplant recipients and safety in FCR001 donors

  • Protocol number: GA43360

    A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclerosis

  • Protocol number: GEMINI-1-NCT04410978

    A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 1)

  • Protocol number: GENERATION1-NCT02565511

    A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.

  • Protocol number: GI19-405-NCT04541173

    A Randomized Phase II Study Evaluating the combination of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)

  • Protocol number: GO42216

    A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS-LIVER)

  • Protocol number: GO42501-NCT04832854

    A PHASE II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB, WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY, IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED RESECTABLE STAGE II, IIIA, OR SELECT IIIB NON&#61485;SMALL CELL LUNG CANCER

  • Protocol number: GORETAG-NCT02777528

    Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta

  • Protocol number: GORETAMBE-NCT03728985

    Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

  • Protocol number: GP-88

    Serum GP-88 Levels in Metastatic Breast Cancer patients: A Prospective Blood Sampling Trial

  • Protocol number: GS-US-200-4334

    A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV

  • Protocol number: GS-US-425-6143

    GS-US-425-6143 - A Phase 1b Randomized, Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GS-8588 in People with HIV-1 who are Virologically Suppressed on Antiretroviral Therapy

  • Protocol number: GU16-260-NCT03117309

    Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260

  • Protocol number: GUARDIAN-REGISTRY

    GUARDIAN

  • Protocol number: HA-PEEK

    A Multi-center, Patient Outcome Registry for a Hydroxyapatite infused PEEK Interbody Fusion Device

  • Protocol number: HARP-NCT02905357

    Heart Attack Research Program (HARP)

  • Protocol number: HBVFB

    Impact of Recent Immigration on Delays in Care Delivery among Foreign-Born with Chronic Hepatitis B Infection

  • Protocol number: HEM-PWRV1US

    HEM-POWR: Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A

  • Protocol number: HEP3

    Human Epilepsy Project 3: Newly Diagnosed Idiopathic Generalized Epilepsy

  • Protocol number: HEPATICADENOMAS

    Outcomes of patients with Benign Liver Lesions

  • Protocol number: HEPE-NCT02190253

    Seroprevalence of Hepatitis E in Organ Transplant subjects

  • Protocol number: HI-PEITHO

    A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study.

  • Protocol number: HIALIVER-NCT03734393

    HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients

  • Protocol number: HIALTF

    Kidney Transplantation in Recipients and Donors with HIV: Long Term Follow Up Study

  • Protocol number: HP-00081403-NCT03652428

    Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer

  • Protocol number: I-SPY2-NCT01042379

    I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

  • Protocol number: I5T-MC-AACI

    Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

  • Protocol number: I8F-MC-GPGN

    The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)

  • Protocol number: I8F-MC-GPHN

    Efficacy and Safety of Tirzepatide Once Weekly versus Placebo for Maintenance of Weight Loss in Participants without Type 2 Diabetes Who Have Obesity or Are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial(SURMOUNT-4)

  • Protocol number: I8H-MC-BDCX

    A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults with Type 2 Diabetes

  • Protocol number: I8H-MC-BDCY

    A Phase 3, Multicenter, Randomized, Parallel-Design, Open Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes treated with Multiple Daily Injection Therapy

  • Protocol number: IBSAMUMH-NCT03094416

    Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

  • Protocol number: IMMUKNOW

    Utility of ImmuKnow, an Immune Cell Function Assay, in a Cardiac Sarcoid Population

  • Protocol number: IMPROVE-NCT04221815

    IMPact on Revascularization Outcomes of intraVascular ultrasound guided treatment of complex lesions and Economic impact (IMPROVE)

  • Protocol number: INCB18424-369

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19–Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

  • Protocol number: INDIVUMED-MHRI

    MedStar Health Biobank and Clinical Library

  • Protocol number: INF-04-NCT04094818

    HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis (SEPSIS-SHIELD)

  • Protocol number: INFORMEXTENDED

    Inform Extended

  • Protocol number: INS-415

    ARISE -A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

  • Protocol number: INS-416

    ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

  • Protocol number: INS1007-301

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis The ASPEN Study

  • Protocol number: INSIGHT012

    An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19

  • Protocol number: INSMED312-NCT02628600

    An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment

  • Protocol number: INTEGRA2017-0908

    The Relationship Between Bacterial Load and the Clinical Outcomes for Integra in Operative Wounds

  • Protocol number: INTRAVESICAL-LACTOBACILLUS

    Intravesical Lactobacillus for Urinary Symptoms Among People with NLUTD Who Use Indwelling Catheters.

  • Protocol number: INVIVO-SKMICRO

    In vivo evaluation of aging-dependent skin microvascular function in HIV infected individuals

  • Protocol number: IO-FDG-MONITOR

    Pilot Study of Serial 18F-FDG Uptake Assessment for Prediction of Anti-PD-1 Therapy Response and Progression Free Survival in Patients with Advanced Melanoma

  • Protocol number: ION-682884-CS2

    A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  • Protocol number: IOV-COM-202-NCT03645928

    A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

  • Protocol number: ISPYCOVID

    I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

  • Protocol number: ISS-20207331-NCT05199311

    A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma

  • Protocol number: ISS-59074-PEMBRO-LENV

    A phase II trial of combination therapy of pembrolizumab and Lenvatinib in patients with locally advanced or metastatic cervical cancer

  • Protocol number: J2W-MC-PYAB

    A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 in Participants with Mild to Moderate COVID-19 Illness

  • Protocol number: J2X-MC-PYAH

    A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy with Monoclonal Antibodies in Participants with Mild to Moderate COVID-19 Illness (BLAZE-4)

  • Protocol number: JAGUAR-CP-0017

    ObJective Analysis to GaUge EVAR Outcomes Through Randomization

  • Protocol number: JENAVALVE-AR-NCT02732704

    JenaValve Pericardial TAVR Aortic Regurgitation Study

  • Protocol number: JENAVALVE-AS-NCT02732691

    JenaValve Pericardial TAVR System Aortic Stenosis Study

  • Protocol number: JEWEL-IDE-NCT05201495

    A Clinical Evaluation of the Jewel™ P&#8208;WCD in Subjects at High Risk for Sudden Cardiac Arrest

  • Protocol number: JTX-8064-101

    Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

  • Protocol number: KETORLACVSCORTICOSTEROID

    Comparing Intraarticular Ketorolac Versus Corticosteroid in Shoulder Adhesive Capsulitis: A triple-blinded randomized controlled trial

  • Protocol number: KETOROLAC

    Effect of Ketorolac Administration on Postoperative Narcotic Utilization and Union Rates in Great Toe Arthrodesis

  • Protocol number: KEYNOTE-992-NCT04241185

    A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

  • Protocol number: KRASG12C

    A retrospective cohort study of patient characteristics and treatment outcomes among patients with KRAS G12C mutated non-small cell lung cancer in the Academic Thoracic Oncology Medical Investigator s Consortium (ATOMIC)

  • Protocol number: KT413-DL-101-NCT05233033

    A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  • Protocol number: KUPFER-BM-3680

    Collection of blood and bone marrow from patients with genetic blood and bone marrow disease

  • Protocol number: L3Y-MC-JPEF-05169567

    postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy

  • Protocol number: LASER-DONORSITE

    Ablative Fractional CO2 LASER Revision for Burn Related Donor Site Scars: A pilot randomized controlled trial.

  • Protocol number: LATHAMFUND

    Interpreting Glycemic Control in People with Type 2 Diabetes and Chronic Kidney Disease

  • Protocol number: LAU-20-01

    A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE II STUDY OF THE EFFICACY AND SAFETY OF LAU-7b IN THE TREATMENT OFADULT HOSPITALIZED PATIENTS WITH COVID-19 DISEASE

  • Protocol number: LEANORA

    evaLuation of variations pharmacokinEtics and phArmacogeNOmics of Ribociclib in rAce-based Cohorts: The LEANORA study

  • Protocol number: LEARN-NCT02488720

    Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial

  • Protocol number: LIMB-ISCHEMIA

    Prospective Study Evaluating the Effect of Skin Pigmentation on Clinical Exam for Determination of Limb Ischemia in Patients with Digital Injuries

  • Protocol number: LIST

    A prospective pilot study to assess for histologic changes on vulvar biopsies in postmenopausal women with Lichen Sclerosus treated with Fractionated CO2 Laser therapy

  • Protocol number: LITERACY

    Limited Health Literacy in Patients with Rotator Cuff Tears: Risk Factors and Outcome Effects

  • Protocol number: LOWRISKTAVR-NCT02628899

    Feasibilty of Transcatheter Aortic Valve Replacement in Low-Risk Patients with Symptomatic, Severe Aortic Stenosis

  • Protocol number: LOWRISKTAVR2-NCT03557242

    Strategies to prevent transcatheter heart valve dysfunction in low risk transcatheter aortic valve replacement

  • Protocol number: LU002

    Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

  • Protocol number: LUNGPACER

    A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning from Mechanical Ventilation in ICU Patients (RESCUE 3)

  • Protocol number: LUNGULTRASOUND-SMOKE

    Use of Philips Lumify Point-of-Care Handheld Ultrasound to Identify Smoke Inhalation Lung Injury.

  • Protocol number: LVADCANNULA

    LVAD Cannula Study: Evaluation of the Anatomic Relationship of Inflow and Outflow Cannula to Flow Dynamics and Clinical Outcomes in Patients with Left Ventricular Assist Devices

  • Protocol number: M19-148

    A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

  • Protocol number: M6-CPAS-NCT04122248

    M6-C™ Artificial Cervical Disc IDE Post-Approval Study

  • Protocol number: M602011069

    Prospective, randomized, double-blind, placebo-controlled, parallel-group trial with an open-label period to investigate the efficacy and safety of NT 201 in the unilateral and bilateral treatment of essential tremor of the upper limb

  • Protocol number: MANTA-ULTRA-CLOSURE

    MANTA ULTRA Closure

  • Protocol number: MAPLE-NCT04793360

    Molecular Assessment and Profiling of Liver Transplant Recipients

  • Protocol number: MARCH

    Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis

  • Protocol number: MATCH-STUDY

    Measurements of AV Access Blood Flow with the Alio Medical Remote Monitoring System to Determine Maturation Status and Patency in ESRD Patients

  • Protocol number: MCLA-128-CL01-NCT02912949

    A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

  • Protocol number: MEDIWOUNDNEXT-NCT04040660

    Use of NexoBrid for Treatment of Acute deep partial and full thickness Burn Injuries

  • Protocol number: MERCK-MK-8591

    A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection

  • Protocol number: MITRAL2-NCT04408430

    The safety and effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra valve with Commander delivery system in patients with symptomatic severe calcific mitral valve disease with severe mitral annular calcification who are not candidates for standard mitral valve surgery.

  • Protocol number: MK-2140-004-00-NCT05144841

    A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Protocol number: MK-3475-587

    A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Protocol number: MK-3475-U01-NCT04165798

    A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

  • Protocol number: MK-6482-011

    An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy

  • Protocol number: MK-6482-022-NCT05239728

    A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK- 3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022)

  • Protocol number: MK-6482-024

    A multicenter, open-label, Randomized Phase 1/2 Study of belzutifan in combination with palbociclib vs belzutifan monotherapy in participants with advanced RCC

  • Protocol number: MK-8591A-017

    A Phase 3, Randomized, Active-Controlled, Open-label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy

  • Protocol number: MK-8591A-019

    A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL

  • Protocol number: MK-8591A-033-0022

    Merck MK-8591A-033-0022

  • Protocol number: MK3475-365-NCT02861573

    Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

  • Protocol number: MK3475-587

    A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

  • Protocol number: MK3475-B98-NCT04938817

    A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)

  • Protocol number: MK3475-B99-NCT04924101

    1L - A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

  • Protocol number: MK3475-U01-NCT04165798

    Master: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

  • Protocol number: MK7339-013

    A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  • Protocol number: MK7684A-006

    Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiation followed by MK- 7684A Versus Concurrent Chemoradiation followed by Durvalumab in Participants with Unresectable, Locally-advanced, Stage III NSCLC Lung

  • Protocol number: ML41591-NCT04302025

    Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients With Stages I-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, or BRAF v600E Molecular Alterations

  • Protocol number: ML42919

    A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab with Atezolizumab plus Bevacizumab in Previously-Treated Advanced Non- squamous NSCLC

  • Protocol number: MNA-3521-012

    AN OPEN LABEL PHASE 1A/B STUDY OF MTL-CEBPA IN COMBINATION WITH A PD-1 INHIBITOR (PEMBROLIZUMAB) IN ADULT PATIENTS WITH ADVANCED SOLID TUMOURS (TIMEPOINT)

  • Protocol number: MOMENTUMCAP-NCT02892955

    MOMENTUM 3: Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3

  • Protocol number: MOR208C310-NCT04824092

    A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]

  • Protocol number: MRDPANC

    Minimal Residual Disease in Resected Pancreatic Adenocarcinoma, a Pilot Study (MRD PANC)

  • Protocol number: MRI-TECHNICAL-DEVELOPMENT

    Technical development of cardiovascular MRI

  • Protocol number: MRX-503-NCT04185363

    An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)

  • Protocol number: MRX-EAP

    An Expanded-Access Program for Maralixibat in Patients with Cholestatic Pruritis Associated with Alagile Syndrome

  • Protocol number: MS-PCSH

    A Pilot Research Study to Evaluate the Impact of a Patient-Centered Specialty Home Model of Care to Treat and Manage Multiple Sclerosis Patients

  • Protocol number: NAPOLI-2-NCT04005339

    Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2)

  • Protocol number: NATURALHISTORY-NCT00009243

    Evaluation, Pathogenesis and Treatment of Patients with or at Risk for Cerebrovascular Disease (A Natural History/Disease Pathogenesis Protocol)

  • Protocol number: NBI-98854-HD3006

    Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntington Disease

  • Protocol number: NCT01524276

    Product Surveillance Registry Base Protocol

  • Protocol number: NCT01574053

    Enroll-HD: A Prospective Registry Study in a Global Huntington’s Disease Cohort A CHDI Foundation Project

  • Protocol number: NCT01892345

    A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial To Evaluate The Safety And Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)

  • Protocol number: NCT02242487

    A 12-Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena)

  • Protocol number: NCT02397096

    A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

  • Protocol number: NCT02403674

    A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects

  • Protocol number: NCT02901717

    MDA 2013-0039:A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infect

  • Protocol number: NCT03209401-2017-0085

    Niraparib Plus Carboplatin in Patients with Homologous Recombination Deficient Advanced Solid Tumor Malignancies

  • Protocol number: NEUROCOGNITION

    Rate of Neurocognitive Decline in Adults with Sickle Cell Disease: an institutional Study

  • Protocol number: NGM707-IO-101

    A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

  • Protocol number: NIC-NCT02720445

    Long Term Nicotine Treatment of Mild Cognitive Impairment

  • Protocol number: NLY01PD1-NCT04154072

    Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease

  • Protocol number: NOD

    Clinical Investigation of Inflammatory Bowel Diseases, Intestinal Failure and Transplantation

  • Protocol number: NODE-301-NCT03464019

    Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301

  • Protocol number: NOPRODLUC0002

    Collection of human-derived, healthy and disease-specific biological samples for the development and control of laboratory assays, procedures and general research.

  • Protocol number: NRG-BN009

    PHASE III TRIAL OF SALVAGE STEREOTACTIC RADIOSURGERY (SRS) OR SRS + HIPPOCAMPALAVOIDANT WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR FIRST OR SECOND DISTANT BRAIN RELAPSE AFTER UPFRONT SRS WITH BRAIN METASTASIS VELOCITY &#8805;4 BRAIN METASTASES/YEAR

  • Protocol number: NRG-BR007-NCT04852887

    A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE </= 18 BREAST CANCER

  • Protocol number: NRG-CC003

    RANDOMIZED PHASE II/III TRIAL OF PROPHYLACTIC CRANIAL IRRADIATION WITH OR WITHOUT HIPPOCAMPAL AVOIDANCE FOR SMALL CELL LUNG CANCER

  • Protocol number: NRG-CC009

    PHASE III TRIAL OF STEREOTACTIC RADIOSURGERY (SRS) VERSUS HIPPOCAMPAL-AVOIDANT WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR 10 OR FEWER BRAIN METASTASES FROM SMALL CELL LUNG CANCER

  • Protocol number: NRG-GI-005-04068103

    Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

  • Protocol number: NRG-GI008-NCT05174169

    Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  • Protocol number: NRG-GY018-NCT03914612

    A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

  • Protocol number: NTX20201

    A Phase 2a, Multicenter, Randomized, Patient and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Acute Single Transected Peripheral Nerve Injury Occurring below the Distal Border of the Brachial Plexus Requiring Surgical Repair.

  • Protocol number: NVL-520-01

    A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)

  • Protocol number: OASIS-NCT04720664

    A Phase II Trial of SM-88 in Patients with Metastatic Hormone Receptor-Positive and HER2-Negative (HR+/HER2-) Breast Cancer

  • Protocol number: OHAND-NCT04035005

    A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  • Protocol number: ON-Q-PUMP

    The impact of the continuous infusion of intraperitoneal analgesics on postoperative pain after minimally invasive hysterectomy: a randomized controlled trial

  • Protocol number: ONC-392-001

    Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study

  • Protocol number: ONO-4059-09-NCT04947319

    An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

  • Protocol number: ONWARD

    A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with noninsulinanti-diabetic treatment, in insulin naïve subjects with type 2 diabetes.

  • Protocol number: ONWARDS-5

    Effectiveness and safety of once weekly insulin icodec used with DoseGuide versus once daily basal insulin analogues in an insulin naïve type 2 diabetes population in a clinical practice setting

  • Protocol number: OPTION-NCT03795298

    Comparison of Anticoagulation with Left Atrial Appendage Closure after AF Ablation

  • Protocol number: ORGANOXMETRAPAS-NCT0552632

    OrganOx metra® New Enrollment Post-Approval Study Protocol

  • Protocol number: ORTHOSPACE-NCT02493660

    A Study to Assess the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears

  • Protocol number: PACER

    A Phase II Study of electron beam intraoperative radiation therapy following chemoradiation in patients with pancreatic cancer with vascular involvement

  • Protocol number: PACES

    Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG (PACeS)

  • Protocol number: PACIFIC4-FSQ

    A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • Protocol number: PALBODCIS-NCT03535506

    Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

  • Protocol number: PANCDX

    Pancreas and Renal Rejection Diagnosis Using Circulating Donor-Derived Cell-free DNA in Peripheral Blood (PANCDx)

  • Protocol number: PANFLUID-REF

    PANCREATIC CYSTIC FLUID REFERENCE SET

  • Protocol number: PARADIGHM-NCT01922440

    A Registry for Patients With Chronic Hypoparathyroidism (PARADIGHM)

  • Protocol number: PARTNERII-PAS

    PARTNER II Post Approval Study Plan

  • Protocol number: PAYA-ART-THERAPY

    Art Therapy in hematology/oncology/bone marrow transplant clinics for Pediatric, Adolescent, and Young Adult patients: A pilot multi-site mixed methods observational study

  • Protocol number: PDDUAL-NCT03402009

    Evaluation of oral anti-parkinsonian medication use in patients with advanced Parkinson s disease with history of Deep Brain Stimulation (DBS) and being treated with Carbidopa Levodopa Enteral Suspension (CLES)

  • Protocol number: PERFORMANCEII-NCT04201132

    Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integrated eMbolic filter, and A Novel Carotid stEnt II

  • Protocol number: PERSONA-TINIDIUM

    A Post-Market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data using the Persona Ti-Nidium Total Knee System and Instrumentation

  • Protocol number: PEX-002

    Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Metastatic Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR Pathway Activation

  • Protocol number: PGX-ACT

    Pharmacogenomics (PGx) Applied to Chronic pain Treatment in primary care (PGx-ACT)

  • Protocol number: PHASEBIO

    A Phase 3, Multicenter, Open-Label, Single-Arm Study of PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure.

  • Protocol number: PICO

    PICO single-use Negative Pressure Wound Therapy System

  • Protocol number: PIVOTAL-IDE

    Left Atrial Posterior Wall Isolation in Conjunction With Pulmonary Vein Isolation Using the Cryoballoon for Treatment of Persistent Atrial Fibrillation (PIVoTAL) - IDE Trial

  • Protocol number: PL101-HD301

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease

  • Protocol number: POLYNOVO-NCT04090424

    A Pivotal Study to Assess the Safety and Effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries.

  • Protocol number: PORTICO-NCT02000115

    PorticoTM Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)

  • Protocol number: PORTICONG-NCT04011722

    Evaluation of the Portico™ NG Transcatheter Aortic Valve in High and Extreme Risk Patients with Symptomatic Severe Aortic Stenosis (Portico NG Approval Study)

  • Protocol number: PR200-104

    A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)

  • Protocol number: PRELUDE-NCT02768402

    Percutaneous Mitral Valve Replacement EvaLuation Utilizing IDE Early Feasibility Study (PRELUDE)

  • Protocol number: PRO2020-0280

    A Multi-Center Phase 1b/2 Study of Daratumumab with Pomalidomide and Dexamethasone in Combination with All-Transretinoic Acid in Patients with Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens

  • Protocol number: PRO2020-0369

    A Phase 2B study of selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide in patients with multiple myeloma relapsing on current therapy

  • Protocol number: PRO2021-1263

    Exploratory Study of Fluoroquinolone Resistance for Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma

  • Protocol number: PROACTIVE

    The Prospera Kidney Transplant Active Rejection Assessment Registry

  • Protocol number: PROACTIVEHF-NCT04089059

    A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients

  • Protocol number: PROGRESS-NCT03777059

    A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PROGRESS)

  • Protocol number: PROTECTIV

    Impella®-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial

  • Protocol number: PSR-APV

    Aortic, Peripheral & Venous (APV) Product Surveillance Registry Platform Base

  • Protocol number: PTK0796-NTM-20203

    A Phase 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adult Subjects with Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)

  • Protocol number: PULSED-AF

    Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF (PULSED AF)

  • Protocol number: R10933-10987-COV-2176

    Regeneron / Prophylactic Protocol / R10933-10987-COV-2176

  • Protocol number: R5093-ONC-1863-NCT04077099

    A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

  • Protocol number: RADCOMP-NCT02603341

    Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

  • Protocol number: RAPA-501-ALLO

    Donation of Blood Lymphocytes for Manufacturing of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for Post-Intubation Stage 3 COVID-19 Disease

  • Protocol number: REDWOOD-NCT04095793

    A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD&#727;9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

  • Protocol number: REFINE-ALS-NCT04259255

    Radicava®/(Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

  • Protocol number: RESSOM

    Establishment of a Liver Tissue Bank

  • Protocol number: RESTORE-NCT02586623

    RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy

  • Protocol number: RETRO

    A2/A2B to B Transplantation Reduces Disparities in Transplant Access While Maintaining Current Levels of Graft and Patient Survival

  • Protocol number: RETROCLK

    Retrospective study to analyze patient and transplant outcomes in recipients of combined Liver and Kidney Transplant (CLK) at the Medstar Georgetown University Hospital (MGUH)

  • Protocol number: RISE-NCT04729751

    Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome

  • Protocol number: ROCHE-ATPO

    Sample Collection for Clinical Performance Evaluation of Elecsys Anti-TPO II

  • Protocol number: ROCHE-BN40423

    A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE

  • Protocol number: ROCHE-NATURALHISTORY

    A multi-site, prospective, longitudinal, cohort study measuring cerebrospinal fluid mutant-huntingtin protein in patients with Huntington's Disease

  • Protocol number: RPNI

    Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation: A Randomized, Prospective Study

  • Protocol number: S1826-NCT03907488

    A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

  • Protocol number: S1931-PROBE

    Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

  • Protocol number: S2015

    Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

  • Protocol number: S2472

    An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphereTM followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphereTM Alone For Hepatocellular Carcinoma (HCC)

  • Protocol number: SAG2424

    Psychometric Validation Study for the Huntington’s Disease Everyday Functioning (Hi-DEF) Scale

  • Protocol number: SAVISCOUT

    SAVI SCOUT® System for Excision of nonpalpable breast lesions: Single institutional study regarding experiences, lessons learned & comparisons to needle localization

  • Protocol number: SBS-NCT01990040

    A Prospective, Multi-center Registry for Patients with Short Bowel Syndrome

  • Protocol number: SECURE

    A ProSpective, MulticEnter, Concurrently Controlled Clinical Study of Chondro-Gide® ArticUlar Cartilage CoveR for the Treatment of Large Chondral Lesions in the KnEe (SECURE)

  • Protocol number: SELECT-NCT03574597

    Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

  • Protocol number: SGNTUC-025-NCT04539938

    A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

  • Protocol number: SHORE-NCT03695601

    SURVEILLANCE HEARTCARE® OUTCOMES REGISTRY (SHORE)

  • Protocol number: SJS-TENS

    Comprehensive Genomic Analysis of Adverse Vaccine and Cutaneous Adverse Drug Reactions

  • Protocol number: SKINGENIX

    A Phase 2, Open-Label, Randomized, Active-Controlled Pilot Study of Investigational Drug, MW-III versus Silvadene® Cream 1% (Silver Sulfadiazine) Topically Applied to Second-Degree Thermal Burns in Adults

  • Protocol number: SMA-CHART-REVIEW-NCT99999999

    Emerging Real-World Use of Nusinersen in Adult Patients with Spinal Muscular Atrophy (SMA) in the US: A Multi-Site Chart Review Study

  • Protocol number: SMART-TRIAL

    SMall Annuli Randomized To Evolut or SAPIEN Trial (SMART Trial)

  • Protocol number: SOS-AMI

    Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction

  • Protocol number: SPECTRAL2

    DeepView SnapShot Portable (DV-SSP): Device Training Study

  • Protocol number: SPINALSINGULARITY-NCT04059159

    ES-NIH-01: Clinical Evaluation of the Connected Catheter Wireless Urinary Prosthesis for Management of chronic Urinary Retention

  • Protocol number: SPLIT

    Prospective Observational Study to Assess Outcomes in Pediatric Liver Transplant Recipients

  • Protocol number: STABLE-NCT03585491

    Shoulder Instability Trial comparing arthroscopic stabilization benefits compared with Latarjet procedure evaluation (STABLE)

  • Protocol number: START-NCT04564833

    A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery (The START Study)

  • Protocol number: STAY-WELL

    The STAY WELL Survivorship Registry

  • Protocol number: STEP-1

    A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study

  • Protocol number: STRATAECR

    Scarring in Stratagraft-treated vs. autograft-treated burn wounds: a clinical and histological investigation

  • Protocol number: STRATASOMA

    A Phase 1/2a, Controlled, Randomized, Multicenter Study Evaluating the Efficacy, Safety, Tolerability of StrataGraft Skin Tissue Overlay of Meshed Autograft (SOMA) in Treatment of Full-Thickness Thermal Burns

  • Protocol number: STRUCTURE-NCT04294004

    A proSpecTive, Randomized, controlled, single-blind, dose-finding, mUlti-Center, parallel group study of the safeTy and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in fibrin) versus local autograft for the treatment of patients undergoing single-level transforaminal lumbar intErbody fusion (the STRUCTURE study)

  • Protocol number: STUDY00000017

    A randomized, double blind, placebo-controlled study to evaluate the impact of Bosutinib on safety, tolerability, biomarkers and clinical outcomes in Dementia with Lewy Bodies (DLB)

  • Protocol number: STUDY00000122

    A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)

  • Protocol number: STUDY00000176-NCT03939689

    A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen (PSMA)-Avid, Chemotherapy-naive, and Progressed on Abiraterone

  • Protocol number: STUDY00000266

    A randomized, double blind, placebo-controlled study to evaluate the impact of K0706 on safety, tolerability, pharmacokinetics and pharmacodynamics and clinical outcomes in Dementia with Lewy Bodies (DLB).

  • Protocol number: STUDY00000313

    Characteristics of mercury vapor poisoning

  • Protocol number: STUDY00000501

    Chronic Stress, QOL, and Physical Activity among Breast Cancer Survivors

  • Protocol number: STUDY00000805

    Biomarkers to Evaluate Immune Related Adverse Events (irAEs) Due to Treatment with Immune Checkpoint Inhibitors (ICIs)

  • Protocol number: STUDY00001007

    Peer Support For Young Adult Women With High Breast Cancer Risk

  • Protocol number: STUDY00001137

    Parent Communication Study IV: Improving Genetic Counseling for BRCA+ Mothers

  • Protocol number: STUDY00001323-NCT04012996

    A Multi-Center, Prospective, Randomized Controlled Trial Comparing the Safety and Effectiveness of prodisc C SK and prodisc C Vivo to Mobi-C Cervical Disc in the Treatment of Two-Level Symptomatic Cervical Disc Disease

  • Protocol number: STUDY00001383

    Breast Imaging Education in Radiology Residency

  • Protocol number: STUDY00001487-TBCRC047

    Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

  • Protocol number: STUDY00001840-NCT04294004

    A proSpecTive, Randomized, controlled, single-blind, dose-finding, mUlti-Center, parallel group study of the safeTy and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in fibrin) versus local autograft for the treatment of patients undergoing single-level transforaminal lumbar intErbody fusion (the STRUCTURE study)

  • Protocol number: STUDY00001920

    Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support

  • Protocol number: STUDY00002130

    A Multicenter Case-Control Study of the Efficacy of EsoGuard&#63195; on Samples Collected Using EsoCheck&#63195;, versus Esophagogastroduodenoscopy, for the Diagnosis of Barrett s Esophagus with and without Dysplasia, and for Esophageal Adenocarcinoma

  • Protocol number: STUDY00002424

    Investigating Exposure to Endocrine Disrupting Chemicals and Poor Sleep in Breast Cancer Survivors

  • Protocol number: STUDY00002550

    Women s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)

  • Protocol number: STUDY00002789

    Informing Latinas about HBOC risk: a Randomized Controlled Trial

  • Protocol number: STUDY00002978

    Genetic Screening for Adult-Onset Inherited Cancer Syndromes in Minors: Policy Implications

  • Protocol number: STUDY00003033-NCT03524118

    A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

  • Protocol number: STUDY00003073-NCT03820947

    Medtronic VenaSeal Spectrum: Global, Post-Market Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease

  • Protocol number: STUDY00003267

    Families SHARE: Development and evaluation of a family health history education toolkit

  • Protocol number: STUDY00003351

    Diet and Cancer-Related Symptoms

  • Protocol number: STUDY00003415

    Supporting Shared Decision Making in Metastatic Breast Cancer

  • Protocol number: STUDY00003424-NCT04564885

    A MULTICENTER, PROSPECTIVE, RANDOMIZED, CLINICAL TRIAL COMPARING THE SAFETY AND EFFECTIVENESS OF THE BAGUERA ® C CERVICAL DISC PROSTHESIS TO THE MOBI - C ® CERVICAL DISC FOR THE TREATMENT OF PATIENTS WITH SYMPTOMATIC CERVICAL DISC DISEASE AT TWO CONTIGUOUS LEVELS

  • Protocol number: STUDY00003425

    Liquid Embolization of Arterial Hemorrhages in the Peripheral Vasculature The LAVA Study

  • Protocol number: STUDY00003772

    Understanding HPV Vaccination Behavior to Prevent Cancer

  • Protocol number: STUDY00003904

    DNA Damage and Breast Cancer Disparities

  • Protocol number: STUDY00004298

    Testing mHealth Delivery of Cognitive Behavioral Therapy for Insomnia to Breast Cancer Survivors

  • Protocol number: STUDY00004338

    Cancer Center Organizational Assessment to Eliminate Outcome Disparities Among Childhood Cancer Survivors

  • Protocol number: STUDY00004349

    Pediatric Tumor Molecular Profiling Outcomes

  • Protocol number: STUDY00004381

    Shared Decision-Making about Palliative Care among Black Patients with Advanced Lung Cancer

  • Protocol number: STUDY00004397

    Scaling Social Determinants of Health Screening, Social Support and Anti-Racism Training to Reduce Inequities in Minority Cancer Survivor Health and Wellbeing in Washington, DC

  • Protocol number: STUDY00004914

    Providing Tobacco Treatment to Patients Undergoing Lung Cancer Screening at MedStar Health: Pilot Study

  • Protocol number: STUDY00005081

    Ecological Momentary Assessment of Quality of Life in Metastatic Breast Cancer

  • Protocol number: STUDY00005120

    Examining the decision to extend endocrine therapy

  • Protocol number: STUDY00005170

    A 104-week, multicenter, single-arm, long-term, phase 3 extension trial investigating the safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) completing the EASE SBS 2 trial

  • Protocol number: STUDY00005285

    Development of an informational support intervention for patients with differentiated thyroid cancer after radioactive iodine treatment

  • Protocol number: SUMMIT-NCT03433274

    Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

  • Protocol number: SUN-PRO00038942

    Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow

  • Protocol number: SURPLUS

    Surgical Resection of Prosthetic Valve Leaflets Under Direct Vision (SURPLUS) Registry

  • Protocol number: TALAPRO-3-MWHC

    TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

  • Protocol number: TARGET-HCC-NCT02954094

    A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma

  • Protocol number: TARGET-NASH-NCT02815891

    A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis

  • Protocol number: TARGETHBV-NCT03692897

    An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection

  • Protocol number: TAVRUNLOAD-NCT02661451

    Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure: a randomized trial (TAVR UNLOAD)

  • Protocol number: TBCRC-052

    MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer

  • Protocol number: TBCRC037-NCT02206984

    A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer

  • Protocol number: TBCRC045-NCT03414658

    A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab

  • Protocol number: TBCRC046-NCT04841148

    A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer ( PALAVY )

  • Protocol number: TBCRCREPOSITORY

    Biospecimen and Outcomes Repository

  • Protocol number: TEASER-NCT02540109

    Targeted Transcranial Electrotherapy to Accelerate Stroke Rehabilitation-Exploratory Trial on Aphasia

  • Protocol number: THUMB-CMC

    Prospective Longitudinal Study of Non-Operative and Operative Thumb CMC Arthritis Interventions

  • Protocol number: TITAN

    TITAN 3-D Wedge System Post-Market Clinical Follow-Up Study

  • Protocol number: TJ003234COV201

    A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects with Severe Coronavirus Disease 2019 (COVID-19)

  • Protocol number: TRAC-AFOUTCOMES

    Tracking Results of Ablations to Combat AF Registry (Formerly the Maze IV Registry)

  • Protocol number: TRANSPORT2-NCT03826030

    TRANScranial direct current stimulation for POst-stroke motor Recovery - a phase II sTudy (TRANSPORT 2)

  • Protocol number: TREATMS-NCT03500328

    TRADITIONAL VERSUS EARLY AGGRESSIVE THERAPY FOR MULTIPLE SCLEROSIS (TREAT-MS) TRIAL

  • Protocol number: TREO-PAS

    Post-Approval Study of the TREO Abdominal Stent- Graft System (P190015) in Patients with Infrarenal Abdominal Aortic and Aorto-iliac Aneurysms

  • Protocol number: TRILUMINATE-NCT03904147

    Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal

  • Protocol number: TRIOMPHE-NCT04471909

    A Multi-Arm, Multi-Center, Non-Randomized, Prospective, Clinical Study to Evaluate the Safety and Effectiveness of the NEXUS™ Aortic Arch Stent Graft System in Treating Thoracic Aortic Lesions Involving the Aortic Arch

  • Protocol number: TRIUMPH-NCT99999999

    Protocol I5Q-MC-B004: preventive TReatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems (TRIUMPH)

  • Protocol number: TRULO-NCT04491552

    TruGraf Long-term Clinical Outcomes Study

  • Protocol number: TTI-622-01-NCT03530683

    A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma

  • Protocol number: TTNS-NCT04350359

    Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder

  • Protocol number: TUMORCOLLAGEN

    Tumor Associated Collagen Signature in Hepatocellular Carcinoma

  • Protocol number: TYR-219-01-NCT04474470

    A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancer

  • Protocol number: UCL-CHDI-1

    HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington s disease

  • Protocol number: UCLAHCCRETRO

    Multi-Institutional Validation of A Novel Prognostic Nomogram Predicting Hepatocellular Carcinoma Recurrence after Liver Transplantation

  • Protocol number: ULURU-BURN

    Prospective Randomized Open Label Multicenter Phase IV Clinical Trial to Compare Transforming Powder Dressing (TPD) to Current Standard of Care (SOC) Dressing Therapies in Acute Partial Thickness Burn Wounds

  • Protocol number: UPIT

    Unleash the Potential of Intestinal Transplant

  • Protocol number: VERIFY-NCT05338697

    Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials (VERIFY)

  • Protocol number: VERILY-NCT04905459

    A multicenter study to evaluate the performance of Automated Retinal Disease Assessment software for the detection of more than mild Diabetic Retinopathy (ARDA mtmDR study)

  • Protocol number: VERISMO

    AN OBSERVATIONAL STUDY OF OCRELIZUMABTREATED PATIENTS WITH MULTIPLE SCLEROSIS TO DETERMINE THE INCIDENCE AND MORTALITY RATES OF BREAST CANCER AND ALL MALIGNANCIES (VERISMO STUDY)

  • Protocol number: VICTORION-2P-NCT05030428

    A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)

  • Protocol number: VICTORION-GSH

    A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (&#8805;70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE)

  • Protocol number: VICTORION-INITIATE

    A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (&#8805;70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE)

  • Protocol number: VIIV

    A multi- site observational study to assess safety and effectiveness of prenatal exposure to Dolutegravir in HIV positive pregnant women

  • Protocol number: VISUAL-HEARTFAIL

    Patient Visualization of Personalized Cardiac Imaging to Improve Health Literacy and Medication Adherence in Patients with Heart Failure

  • Protocol number: VS-6766-NCT04620330

    A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

  • Protocol number: VULVIE

    A randomized controlled trial of Vulvar fractionated CO2-Laser therapy with and without concomitant topical clobetasol propionate 0.05% ointment for treatment of Vulvar lichen sclerosus

  • Protocol number: VYXEOS

    Phase IB/II of CPX-351 for Relapse Prevention in AML

  • Protocol number: WA42293

    A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

  • Protocol number: WATCH-RWE

    WATCHMAN FLX Real World Evidence Protocol

  • Protocol number: WATS-NCT02988934

    The WATS3-D (Wide Area Transepithelial Sample Biopsy with 3-Dimensional Computer-Assisted Analysis) U.S. Registry

  • Protocol number: WELLDOC

    Safety of a Real-time Continuous Glucose Monitor-based Insulin Bolus Calculator: The CGM-IBC; Study B

  • Protocol number: WF-1806-NCT03998202

    Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer (M&M) (NCORP)

  • Protocol number: WHITEMATTER-NCT03366129

    The Natural History of Blood-Brain Barrier Disruption in Stroke Patients with White Matter Hyperintensities (A Cohort Study)

  • Protocol number: WN39658

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Early (prodromal to mild) Alzheimer's Disease

  • Protocol number: WN42171

    AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE

  • Protocol number: WN43194

    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)

  • Protocol number: Z11102

    Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)

  • Protocol number: ZYGOOD-NCT04000867

    Treatment for Foot Pain Caused by Diabetic Neuropathy Using Recurrent TransCutaneous Magnetic Stimulation (TCMS)

All clinical trials

Our trials are carefully planned research studies that have led to important discoveries such as new drugs, procedures, and diagnostic approaches that make our lives better.

Volunteering in our trial offers potential benefits, including:

  • The opportunity to become involved in the testing of a new drug that may have potential to improve your condition

  • Close contact with the study team for management of your disease

  • Contributing to medical science, which may help others now and in the future

Frequently asked questions

  • Q: Why volunteer?

    A: Does volunteering for a clinical trial make sense for you? The following information will help you to decide.

  • Q: What are clinical trials and why are they important?

    A: Clinical trials are carefully planned research studies that have led to important discoveries such as new drugs, devices, procedures, biologics, and diagnostic approaches. These new discoveries make our lives better such as new medicines to treat cancer, diabetes, and other diseases. Some other words for clinical trials are research, survey, or experiment.

    Know what you are getting into and don’t be afraid to ask questions. A clinical trial may or may not help you personally. The results from the study could help others who have a health problem. Taking part in research is voluntary. It is your decision!

  • Q: Why do we need clinical trials?

    A: A series of clinical trials for each possible treatment must be done before the Food and Drug Administration (FDA) will approve a drug, procedure, or device. Many of the trials done at MedStar Health Research Institute are trials testing possible drugs or devices. A drug must be shown to be safe and useful for public use before the FDA can approve it.

    From the lab bench to the drug store, developing a new drug is a long and expensive process. It is estimated to take about 10 years and $800 million to bring one new drug to market (R & D Directions, January 2002).

  • Q: Are clinical trials safe?

    A: Protections have been put in place to safeguard your rights, safety, and privacy in research. Many layers of oversight include an institutional review board (ethical review board), the Food and Drug Administration (FDA), and periodic monitoring of study data by independent experts, patient advocates, community advisory board members, and community partners.

    • Screening trials test the best way to detect certain diseases or health conditions

    • Diagnostic trials determine better tests or procedures for diagnosing a particular disease or condition

    • Treatment trials test new treatments, new combinations of drugs, or new approaches to surgery

    • Quality of life trials explore and measure ways to improve the comfort and quality of life of people with a chronic illness

  • Q: Who can participate in a clinical trial?

    A: People with the condition being studied or healthy people can volunteer to take part in a clinical trial. Each study has specific entry requirements such as age or a medical condition necessary for participation.

    The doctor in charge of the study must review the volunteers' medical history to determine if he/she is eligible to participate based on strict study conditions called entry criteria.

  • Q: Who is in charge of a clinical trial?

    A: A medical doctor is usually responsible for carrying out the study according to the study protocol. Before a clinical trial can begin to enroll volunteers, an Institutional Review Board (IRB) must approve it. The IRB is a committee made up of healthcare experts that review each study to protect patient rights and ensure the safety of research volunteers. The IRB also ensures the research is scientifically sound and is involved in the review of safety issues throughout the study.

  • Q: What is informed consent?

    A: One of the documents the IRB must review and approve is called an Informed Consent Form. This is provided to volunteers who are interested in participating in a clinical trial program. The informed consent includes everything a volunteer needs to know about the study so that he/she can make an informed decision as to whether or not to participate. The process allows volunteers to ask questions. Volunteers are encouraged to take their time in making a decision before signing the consent and joining the study. You and your family should feel completely comfortable with your decision to participate before you sign the consent.

  • Q: What are the benefits to being in a clinical trial?

    A: Once enrolled in a clinical trial, many volunteers find there are a number of potential benefits to participation. These can include:

    • The opportunity to become involved in the testing of a new drug that may have potential to improve your condition.

    • Close contact with the study team for management of your disease.

    • Contributing to medical science, which may help others now and in the future.

    However, volunteers understand that there may not be any benefit to participating in a study.

  • Q: Why do we need diversity in a research?

    A: Race, ethnicity, age, and other factors can affect how people respond to medicine.

  • Q: Why do many still feel uneasy about being part of a clinical trial?

    A: The Tuskegee Syphilis Study and the cancer cells taken from Henrietta Lacks without her knowledge are two reasons for the continued distrust with the African American community. Today, there is low participation in clinical trials from African Americans. We may not know if certain treatments will be effective in this population.

  • Q: Will my health insurance pay for a clinical trial?

    A: Federal law requires insurance companies to cover routine costs, which are things you need regardless of a clinical trial. If the study sponsor requires extra testing, they will typically cover the cost.

  • Q: Can I drop out of a clinical trial and still receive quality care?

    A: You are in control. If you decide you do not want to participate anymore, you can withdraw at any time. You will receive the same high-quality care at MedStar Health. Your clinical team may ask to continue monitoring you for a period of time to assess effects of the treatment you have already received.

  • Q: Are clinical trials considered a last-ditch effort for patients?

    Phases of Clinical Research

    A: Not true at all! Clinical trials allow access to treatments that are up and coming but not yet available to the general population.

  • Q: Interested in participating in a clinical trial by MedStar Health?

    A: Email JoinResearch@MedStar.net or call 833-998-0900 (toll-free) to learn more and ask about our open studies.